Dublin drug company raises €18 million

Opsona Therapeutics, a drug development company based in Dublin, has completed a Series B round of funding.

The round, in which four venture capitalist funds participated, raised €18 million (£16 million) to support clinical trials targeting inflammatory diseases such as lupus and rheumatoid arthritis.

As part of the financing, Florent Gros, managing director at early-stage healthcare investor Novartis Venture Fund, and Dr Manus Rogan, managing partner at Dublin-based Fountain Healthcare Partners, will join the board of directors.

The other two firms named as investors in the round are life sciences investor Inventages Venture Capital and Seroba Kernel Life Sciences, which has offices in Ireland and the UK.

Opsona has also announced the opening of a new laboratory in Switzerland.

Nick Britton

Nick Britton

Nick was the Managing Editor for growthbusiness.co.uk when it was owned by Vitesse Media, before moving on to become Head of Investment Group and Editor at What Investment and thence to Head of Intermediary...